

ÖZGEÇMİŞ

DÜZENLEME TARİHİ	Ekim 2014		
ÜNVANI ADI SOYADI	Prof. Dr. Engin Ulukaya		
YAZIŞMA ADRESİ	Uludağ Üniversitesi Tıp Fakültesi Tıbbi Biyokimya Anabilim Dalı Görükle / BURSA 16059 Bursa/Türkiye		
DOĞUM YILI	1965		
TEL	0224 2953913	GSM	0533 4305932
E-POSTA	eulukaya@uludag.edu.tr	FAX	0224 4428245

EĞİTİM

MEZUNİYET TARİHİ	DERECE	ÜNİVERSİTE-FAKÜLTE-BÖLÜM/ANABİLİM DALI
1996-2000	Doktora	University of Leeds
1992-1995	Tıpta Uzmanlık	Uludağ Üniversitesi
1981-1988	Lisans	İstanbul Üniversitesi –Cerrahpaşa Tıp Fakültesi

*(Lisans, Yüksek Lisans, Doktora, Tıpta Uzmanlık)

AKADEMİK VE MESLEKİ DENEYİM

KURUM/KURULUŞ	ÜLKE	ŞEHİR	BÖLÜM/BİRİM	GÖREV	GÖREV DÖNEMİ
Uludağ Üniversitesi	Türkiye	Bursa	Tıbbi Biyokimya A.D.	Prof. Dr.	2009-
Uludağ Üniversitesi	Türkiye	Bursa	Biyokimya A.D.	Doç Dr.	2003-2009
Uludağ Üniversitesi	Türkiye	Bursa	Biyokimya A.D.	Yrd.Doç Dr.	2000-2003
Technische Universität München	Almanya	Münih	Clinical Research Unit, Dept. Obstetrics and Gynecology	Araştırmacı	Temmuz – Eylül 2007
University of London	İngiltere	Londra	Pathology Department	Araştırmacı	Ekim-Aralık 2000

*(Başlangıç Tarihi – Bitiş Tarihi)

BİLİMSEL İLGİ VE ÇALIŞMA ALANI

1. Kanser kök hücre çalışmaları: Yeni anti-kanser ajanların hücre soylarından ya da hasta dokularından izole edilen kanser kök hücreleri üstündeki sitotoksik etkilerinin araştırılması.
2. Tümör kemosenitivite/direnç çalışmaları: Kanser hastalarından alınan dokulardan kanser hücrelerinin izole edilmesi ve bu hücreleri kullanarak hastaların çeşitli kemoterapötik ajanlara yanıtının (sensitivitesinin yada rezistansının) laboratuvar koşullarında in vitro olarak test edilmesine dayanarak hastaya özgü kemoterapi dizaynı (ONKOGRAM). Onkogram yönteminin geliştirilmesine yönelik laboratuvar çalışmaları
3. Hücre ölümü çalışmaları: Apoptozisin kanser gelişimi ve tedavisindeki rolünün hücreSEL ve moleküler düzeyde çalışılması. M30 antijen ve kemoterapiye yanıtla ilişkisi. Tedaviye yanıtı belirlemede kullanılabilecek yeni biobelirteç keşfi.
4. Sitotoksosite yöntemleri ile ilgili metodolojik çalışmalar: Genel olarak hücre ölümü / sitotoksosite testlerinin metodolojik değerlendirilmeleri. Bu testlerin in vitro ve in vivo uygulamaları
5. Anti-kanser ajan keşfi çalışmaları: Anorganik sentez, bitki-ekstraktları, nanopartiküller vs. kullanılarak yeni ajan geliştirme çalışmaları ve bu ajanların sitotoksik etkilerinin prelinik değerlendirilmesi (in vitro ve in vivo) (drug discovery and development)

DİĞER AKADEMİK FALİYETLER (Hakemlik/Danışmanlık/Editörlük Deneyimi)

Son bir yılda uluslararası indekslere kayıtlı makale/derleme için yaptığınız danışmanlık sayısı			18
Son bir yılda projeler için yaptığınız danışmanlık sayısı			24
Yayınlara aldığınız toplam atıf sayısı			~1000
Danışmanlığımı yaptığınız öğrenci sayısı		Tamamlanan	Devam Eden
	Yüksek Lisans	2	-
	Doktora	1	5
	Uzmanlık	3	1
Diğer Faaliyetler (Eser/görev/faaliyet/sorumluluk/olay/üyelik vb.)	<p>1- EACR (European Association for Cancer Research), Council Member (2009 -)</p> <p>2- Moleküler Kanser Araştırma Derneği (MOKAD), Yönetim Kurulu Başkanı. (2008-)</p> <p>Ülkemizde biri uluslar arası (4. EORTC Pathobiology Annual Meeting & 1. IMCR Congress), ikisi uluslar arası (12 ve 15 yabancı konuşmacı) katılımlı ve ikisi ulusal kanser araştırma sempozyumları düzenlemek.</p> <p>3- EORTC (European Organization for Research and Treatment of Cancer) Pathobiology grubu (Asil Üyelik, 2009-)</p> <p>4- Uludağ Üniversitesi Tıp Fakültesi Dergisi (Yardımcı Editör)</p> <p>5- Onkogram/Sitotoksiste çalışmaları için Prof. Dr. Ian Cree'nin laboratuvarında (Londra ve Portsmouth, İNGİLTERE) 2 kez kısa dönem (~2 ay) çalışmalar; 1996-2000 yıllarında University of Leeds (İNGİLTERE)'de fenretinid, sitotoksiste, apoptozis konulu biyokimya ve moleküler biyoloji doktorası (PhD)</p> <p>6- International Society for Chemosensitivity Testing in Oncology (ISCO) (Üyelik)</p>		

YAYINLAR

SCI, SSCI, AHCI, PUBMED indekslerine giren dergilerde yayınlanan makaleler	77*
1- Ulukaya E and Güler A H. General Practitioners' Opinions about the Basic Sciences in Relation to Medicine. <i>Biochemical Education</i> , 23(3):143, 1995	
2- Kaya H, Delibaş N, Serteser M, Ulukaya E and Özkaya O. The Effect of Melatonin on Lipid Peroxidation During Radiotherapy in Female Rats. <i>Strahlentherapie und Onkologie</i> , 175:285-288, 1999	
3- Ulukaya E and E J Wood. Fenretinide and Its Relation to Cancer. <i>Cancer Treatment Reviews</i> , 25:229-235, 1999	
4- Ulukaya E, Kurt A and Wood E J. 4-(N-Hydroxyphenyl)retinamide can Selectively Induces Apoptosis in Human Epidermoid Carcinoma Cells but not in Normal Dermal Fibroblasts. <i>Cancer Investigation</i> 19(2): 1-12, 2001	
5- Ulukaya E, Pirianov G, Kurt M A, Wood E J and Mehmet H. Fenretinide induces cytochrome c release, caspase 9 activation and apoptosis in the absence of mitochondrial membrane depolarisation. <i>Cell Death Differ</i> 10:856-859, 2003	
6- Ulukaya E, Colakogullari M and Wood E J. Interference by anti-cancer chemotherapeutic agents in the MTT - tumor chemosensitivity assay. <i>Chemotherapy</i> 50:43-50, 2004	
7- Demiray M, Gülten M, Manavoğlu O, Evrensel T, Ulukaya E, Yerci O, Kanat O, Arslan M, Kurt E, Gonullu G, Demiray H, Gulden T, Memik F. Evaluation of the effects of helicobacter pylori eradication therapy on gastric antral epithelial hyperproliferation: a prospective, sixth-month follow-up study. <i>Hepatogastroenterology</i> . 51(59):1531-5, 2004	
8- Karasu Z, Ulukaya S, Ayanoglu HO, Basturk B, Ulukaya E, Akyildiz M, Tokat Y. Cytokine Gene Polymorphism and Early Graft Rejection in Liver Transplant Recipients. <i>Transplant Proc.</i> 36(9):2791-5, 2004	
9- Kaya H, Ozkaya O, Sezik M, Arslanoglu E, Yilmaztepe A, Ulukaya E. Effects of raloxifene on serum malondialdehyde, erythrocyte superoxide dismutase, and erythrocyte glutathione peroxidase levels in healthy postmenopausal women. <i>Maturitas</i> . 14:50(3):182-8, 2005	
10- Yilmaztepe A, Ulukaya E, Ersoy C, Yılmaz M and Tokullugil AH. Investigation of Fecal Pancreatic Elastase-1 Levels in Type 2 Diabetic Patients. <i>Turkish Journal of Gastroenterology</i> . 16(2):75-80, 2005	
11- Demiray M, Ulukaya E, Arslan M et al... Response to Neoadjuvant Chemotherapy in Breast Cancer Could be Predictable by Measuring a Novel Serum Apoptosis Product, Caspase-Cleaved Cytokeratin 18: A Prospective Pilot Study. <i>Cancer Invest.</i> 24(7):669-76, 2006.	
12- Colakogullari M, Ulukaya E, Yilmaztepe A, Ocakoglu G, Yılmaz M, Karadag M, Tokullugil A. Higher Serum Nitrate Levels Are Associated With Poor Survival in Lung Cancer Patients. <i>Clinical Biochemistry</i> 39:898-903, 2006.	
13- Ulukaya E, Yilmaztepe A, Akgöz S, Linder S, Karadag M. The Levels of Caspase-cleaved Cytokeratin 18 are Elevated in Serum from Patients with Lung Cancer and Helpful to Predict the Survival. <i>Lung Cancer</i> . 56:399-404, 2007	
14- Yılmaz Y, Dolar E, Ulukaya E, et al. Soluble forms of extracellular cytokeratin 18 may differentiate simple steatosis from nonalcoholic steatohepatitis. <i>World J Gastroenterol</i> . 13:837-844, 2007	
15- Yilmaztepe A, Ulukaya E, Zik B, et al... Soluble Vascular Endothelial Growth Factor Receptor-1 (sVEGFR-1) is Decreased in Lung Cancer Patients Showing Progression: A Pilot Study. <i>Cancer Invest.</i> 25(5):322-7, 2007	
16- Colakogullari M, Ulukaya E, Oral AY, et al. The involvement of IL-10, IL-6, IFN- γ , TNF- α and TGF- β Gene	

Polymorphisms in Lung Cancer among Turkish Population. <i>Cell Biochem Funct.</i> 26(3):283-90, 2008
17- Kaya H, Desdicioglu R, Sezik M, Ulukaya E , et al. Does sphingosine-1-phosphate have a protective effect on cyclophosphamide- and irradiation-induced ovarian damage in the rat model? <i>Fertil Steril.</i> 89(3):732-5, 2008
18- Dasdag S, Akdag Z, Ulukaya E , et al. Mobile phone exposure does not induce apoptosis on spermatogenesis in rats. <i>Arch Med Res.</i> 39(1):40-4, 2008
19- Ulukaya E , Ozdikicioglu F, Yilmaztepe A et al. The MTT assay yields a relatively lower result of growth inhibition than the ATP assay depending on the chemotherapeutic drugs tested. <i>Toxicol In Vitro.</i> 22(1):232-9, 2008
20- Akkaya O, Kiyici M, Yilmaz Y, Ulukaya E , Yerci O. Clinical significance of activity of ALT enzyme in patients with hepatitis C virus. <i>World J Gastroenterol.</i> 13:5481-5485, 2007
21- Ozdikicioglu F, Ulukaya E , Yilmaztepe AO. The Differential Anticancer Effects of Green Tea in Estrogen Receptor-Positive and Estrogen Receptor-Negative Human Breast Cancer Cell Lines. <i>Adv Mol Med.</i> 3:69-75, 2007
22- Yilmaztepe OA, Ulukaya E, Yilmaz Y. VEGF, VEGF-receptors and lung cancer. <i>Adv Mol Med.</i> 3:15-21, 2007
23- Ulukaya S, Basturk B, Kilic M, Ulukaya E . Cytokine gene polymorphism and postreperfusion syndrome during orthotopic liver transplantation. <i>Transplant Proc</i> 40: 1290-1293, 2008
24- Yilmaz Y, Ulukaya E , Dolar E. "A biomarker biopsy" for the diagnosis of NASH: promises from CK-18 fragments. <i>Obes Surg.</i> 2008 Nov;18(11):1507-8
25- Yilmaz Y, Ulukaya E , Dolar E. Serum M30 levels: A potential biomarker of severe liver disease in nonalcoholic fatty liver disease and normal aminotransferase levels. <i>Hepatology</i> , 49(2):697, 2009
26- Yilmaz Y, Dolar E, Ulukaya E . Commentary on the study of Vos et al. "Cytokeratin 18, a marker of cell death, is increased in children with suspected nonalcoholic fatty liver disease. <i>J Pediatr Gastroenterol Nutr.</i> 49(3):371, 2009
27- Yilmaz Y, Ulukaya E , Dolar E. The quest for liver fibrosis biomarkers: Promises from the enhanced liver fibrosis panel and beyond. <i>Hepatology</i> , 49(3):1056-7, 2009
28- Yilmaz Y, Ulukaya E , Gul OO, Arabul M, Gul CB, Atug O, Oral AY, Aker S, Dolar E. Decreased plasma levels of soluble receptor for advanced glycation endproducts (sRAGE) in patients with nonalcoholic fatty liver disease.. <i>Clin Biochem.</i> 42(9):802-7, 2009.
29- Yilmaz Y, Dolar E, Ulukaya E , Akgoz S, Keskin M, Kiyici M, Yerci O, Oral AY, Gul CB, Gurel S, Nak SG, Gulden M. Elevated serum levels of caspase-cleaved cytokeratin 18 (CK18-Asp396) in patients with nonalcoholic steatohepatitis and chronic hepatitis C. <i>Med Sci Monit.</i> 15(4):CR189-93, 2009
30- Yilmaz Y, Ulukaya E , Atug O, Dolar E. Serum concentrations of human angiopoietin-like protein 3 in patients with nonalcoholic fatty liver disease: association with insulin resistance. <i>Eur J Gastroenterol Hepatol.</i> 21(11):1247-51, 2009.
31- Senturk T, Aydinlar A, Yilmaz Y, Yilmaztepe Oral A, Ozdabakoglu O, Ulukaya E . Serial changes in circulating M30 antigen, a biomarker of apoptosis, in patients with acute coronary syndromes: relationship with the severity of coronary artery disease. <i>Coron Artery Dis.</i> 20(8):494-8, 2009.
32- Dasdag S, Akdag MZ, Ulukaya E , Uzunlar AK, Ocak AR. Effect of mobile phone exposure on apoptotic glial cells and status of oxidative stress in rat brain. <i>Electromagn Biol Med.</i> 2009;28(4):342-54.
33- Taskin E, Akgün-Dar K, Kapucu A, Osanc E, Dogruman H, Eraltan H, Ulukaya E . Apoptosis-Inducing Effects of <i>Morinda citrifolia L.</i> (Noni) and Doxorubicin on the Ehrlich Ascites (EAC) Tumor in Balb-c Mice. <i>Cell Biochemistry and Function</i> 27:542-546, 2009
34- Ulukaya E , Yilmaz Y, Moshkovskii S, Vlaslova M, Pyatnitskiy M, Ozlen A, Dolar E. Proteomic analysis of serum in patients with nonalcoholic steatohepatitis using MALDI-TOF/MS. <i>Scandinavian Journal of Gastroenterology.</i> 44:1471-6, 2009
35- Gul OO, Tuncel E, Yilmaz Y, Ulukaya E , Gul CB, Kiyici S, Yilmaztepe Oral A, Guclu M, Ersoy C, Imamoglu S. Comparative effects of pioglitazone and rosiglitazone on plasma levels of soluble receptor for advanced glycation end products in type 2 diabetic patients. <i>Metabolism-Clinical and Experimental.</i> 59: 64-69, 2010
36- Linder S, Olofsson MH, Herrmann R, Ulukaya E . Utilization of cytokeratin-based biomarkers for pharmacodynamic studies. <i>Expert Rev Mol Diagn.</i> 10: 353-359, 2010
37- Ulukaya E , Acilan C, Yilmaz M, Yilmaztepe-Oral A, Ari F, Zik B, Ursavas A, Tokullugil AH. sFas levels increase in response to cisplatin-based chemotherapy in lung cancer patients. <i>Cell Biochem Funct.</i> 28: 565-570,2010
38- Ulukaya S, Ulukaya E , Alper I, Yilmaztepe-Oral A, Kilic M. Soluble Cytokeratin-18 Biomarkers May Provide Information of the Type of Cell Death During Early Ischemia and Reperfusion Periods of Liver Transplantation. <i>Clin Transplant.</i> 24: 848-854, 2010
39- Akdag MZ, Dasdag S, Ulukaya E , Uzunlar AK, Kurt MA, Taşkın A. Effects of Extremely Low-Frequency Magnetic Field on Caspase Activities and Oxidative Stress Values in Rat Brain. <i>Biol Trace Elem Res.</i> 138: 238-249, 2010
40- Ari F, İkitimur EI, Ulukaya E . The ATP assay, but not the MTT assay, detects further cytotoxicity of the combination of anthracycline-based therapy with histone deacetylase inhibitor (Valproic acid) in breast cancer cells. <i>Turk J Biochem.</i> 35: 293-299, 2010
41- Yilmaz Y, Yonal O, Kurt R, Ari F, Oral AY, Celikel CA, Korkmaz S, Ulukaya E , Ozdogan O, Imeryuz N, Avsar E, Kalayci C. Serum fetuin A/alpha 2HS-glycoprotein levels in patients with non-alcoholic fatty liver disease: relation with liver fibrosis. <i>Annals of Clinical Biochemistry.</i> 47: 549-553, 2010
42- Yilmaz Y, Ulukaya E . Molecular signatures of nonalcoholic fatty liver disease:The present and future. <i>Hepatology.</i> 51:1866-1866, 2010
43- Yilmaz Y, Yonal O, Kurt R, Oral AY, Eren F, Ozdogan O, Ari F, Celikel CA, Korkmaz S, Ulukaya E , Imeryuz N, Kalayci C, Avsar E. Serum levels of osteoprotegerin in the spectrum of nonalcoholic fatty liver disease. <i>Scandinavian Journal Of Clinical & Laboratory Investigation.</i> 70: 541-546, 2010
44- E. Guney, V.T. Yilmaz, F. Ari, O. Buyukgungor, E. Ulukaya . Synthesis, characterization, structures and cytotoxic activity

of palladium(II) and platinum(II) complexes containing bis(2-pyridylmethyl)amine and saccharinate. <i>Polyhedron</i> .30(1) 114-112, 2011
45- Yilmaz Y, Yonal O, Kurt R, Alandab YO, Ozdogan O, Celikel CA, Ulukaya E , Imeryuz N, Kalayci C, Avsar E. Circulating Levels of Vascular Endothelial Growth Factor A and Its Soluble Receptor in Patients with Biopsy-proven Nonalcoholic Fatty Liver Disease. <i>Archives of Medical Research</i> 42:38-43, 2011
46- Ulukaya E , Yagci A, Zik B, Sevimli A, Yilmaztepe OA, Akgoz S, Bayer S, Ursavas A. The Expressions of pAkt and PTEN in Lung Cancer Patients 24 Hours After the Cisplatin-Based Chemotherapy: A Prospective Pilot Study. <i>UHOD</i> . 21:26-33, 2011
47- Ulukaya E , Karaagac E, Ari F, Oral AY, Adim SB, Tokullugil AH, Evrensel T. Chemotherapy Increases Caspase-Cleaved Cytokeratin 18 in the Serum of Breast Cancer Patients. <i>Radiology and Oncology</i> 45: 116-122, 2011
48- Ulukaya E , Acilan C, Yilmaz Y. Apoptosis: Why and how does it occur in biology? <i>Cell Biochem Func</i> 29: 468-480, 2011
49- Ari F, Napieralski R, Ulukaya E , Dere E, Colling C, Honert K, Krüger A, Kiechle M, Schmitt M.. Modulation of protein expression levels and DNA methylation status of breast cancer metastasis genes by anthracycline-based chemotherapy and the demethylating agent decitabine. <i>Cell Biochem Funct. Cell Biochem Funct.</i> 29(8):651-9, 2011
50- Ulukaya E . Acilan C, Ari F, İkitimur E, Yilmaz Y. A glance at the methods for detection of apoptosis qualitatively and quantitatively. <i>Turk J Biochem</i> 36:261-269, 2011
51- Ulukaya E , Ari F, Dimas K, Sarimahmut M, Guney E, Sakellaridis N, Yilmaz VT. Cell death-inducing effect of novel palladium(II) and platinum(II) complexes on non-small cell lung cancer cells in vitro. <i>J Cancer Res Clin Oncol</i> . 137(10):1425-34, 2011.
52- Ulukaya E , Ari F, Dimas K, İkitimur EI, Guney E, Yilmaz VT. Anti-cancer activity of a novel palladium(II) complex on human breast cancer cells in vitro and in vivo. <i>Eur J Med Chem</i> . 46(10):4957-63, 2011
53- Yilmaz Y and Ulukaya E . Toward a Biochemical Diagnosis of NASH: Insights From Pathophysiology For Distinguishing Simple Steatosis From Steatohepatitis. <i>Current Medicinal Chemistry</i> . 18:725-732, 2011
54- Maria Grazia Daidone, et al. Identification, validation and clinical implementation of cancer biomarkers: Translational strategies of the EORTC PathoBiology Group. <i>EJC Supp</i> 9, no. 2: 120–127, 2012
55- Yerlikaya A, Okur E, Ulukaya E .The p53-independent induction of apoptosis in breast cancer cells in response to proteasome inhibitor bortezomid. <i>Tumour Biol</i> . 2012 Apr 4. [Epub ahead of print]. PMID:22477712
56- Ferda ARI, Serap CELIKLER, Seyhan ORAN, Necmiye BALIKCI, Sule OZTURK, Mustafa Z Ozel, Dilek Ozyurt, Engin ULUKAYA . Genotoxic, Cytotoxic and Apoptotic Effects of Hypogymnia physodes (L.) Nyl. on Breast Cancer Cells. <i>Environ Toxicol</i> . 2012 Aug 21. doi: 10.1002/tox.21809. [Epub ahead of print]
57. Ari F, Sarimahmut M, Ulukaya E . Peripherally located A431 cells are more sensitive to cell death induced by exogenous oxidative stress. <i>Current Signal Transduction Therapy</i> . 7: 202-208, 2012
58. Bozcuk H, Abali H, Coskun S, Lung Cancer Committee of Turkish Oncology Group.The correlates of benefit from neoadjuvant chemotherapy before surgery in non-small-cell lung cancer: a metaregression analysis. <i>World J Surg Oncol</i> . 2012 Aug 9;10(1):161. doi: 10.1186/1477-7819-10-161.
59. Tsimplouli C, Pantazis P, Alevizopoulos K, Ulukaya E , Dimas K. Patient-Derived Xenografts: Real-Time Modeling of Cancer, Leon V. Berhardt (Ed), <i>Advances in Medicine and Biology</i> , Volume 57, Nova Science Publishers, NY, USA, 2012. BOOK CHAPTER
60. Saliha Sahin, Ferda Ari, Cevdet Demir, Engin Ulukaya . Isolation of major phenolic compounds, antioxidant and cytotoxic activities of extracts from <i>Prunella L.</i> species grown in Turkey. <i>Journal of Food Biochemistry</i> . (Accepted).
61. İcsel C, Yilmaz VT, Ari F, Ulukaya E , Harrison WT. trans-Dichloridopalladium(II) and platinum(II) complexes with 2-(hydroxymethyl)pyridine and 2-(2-hydroxyethyl)pyridine: Synthesis, structural characterization, DNA binding and in vitro cytotoxicity studies. <i>Eur J Med Chem</i> . 2013 Feb;60:386-94. doi: 10.1016/j.ejmech.
62. Ari F, Napieralski R, Ulukaya E . Changes in Gene Methylation Following Chemotherapy in Breast Cancer Cell Lines. <i>Turk J Biochem (Accepted)</i>
63. Ceyda İcsel, Veysel T. Yilmaz, Aysegul Golcu, Engin Ulukaya , Orhan Buyukgungor. Synthesis, crystal structures, DNA binding and cytotoxicity of two novel platinum(II) complexes containing 2-(hydroxymethyl)pyridine and pyridine-2-carboxylate ligands. <i>Bioorg Med Chem Lett</i> . 2013 Feb 8. doi:pii: S0960-894X(13)00152-2. 10.1016/j.bmcl
64. Cevatemre B, Ari F, Sarimahmut M, Yilmaztepe AO, Dere E, Kacar O, Adiguzel Z, Acilan C, Ulukaya E . Combination of fenretinide and indole-3-carbinol results in synergistic cytotoxic activity inducing apoptosis against human breast cancer cells <i>in vitro</i> . <i>Anticancer Drugs (Accepted)</i>
65. Ari F, Ulukaya E , Sarimahmut M, Yilmaz VT. Palladium(II) saccharinate complexes with bis(2-pyridylmethyl)amine induce cell death by apoptosis in human breast cancer cells in vitro (Accepted by Bioorganic & Medicinal Chemistry)
66. Ulukaya E , Frame F, et al. Differential Cytotoxic Activity of a Novel Palladium-Based Compound on Prostate Cell Lines, Primary Prostate Epithelial Cells and Prostate Stem Cells. (Accepted by PLOS ONE).
67. Coskun MD, Ari F, Oral AY, Sarimahmut M, Kutlu HM, Yilmaz VT, Ulukaya E . Promising anti-growth effects of Palladium(II) complex saccharinate complex of terpyridine by inducing apoptosis on transformed fibroblasts in vitro. (Accepted by <i>Bioorg and Med Chem</i>)
68. Mehmet Zulkuf Akdag , Suleyman Dasdag , Ali Kemal Uzunlar, Engin Ulukaya , Arzu Yilmaztepe Oral, Necla Çelik , Feyzan Akşen. Can safe and long-term exposure to extremely low frequency (50 Hz) magnetic fields affect apoptosis, reproduction, and oxidative stress. <i>Int J Radiat Biol</i> . 89(12):1053-60, 2013
69. Kacar O, Adiguzel Z, Yilmaz VT, Cetin Y, Cevatemre B, Arda N, Baykal AT, Ulukaya E , Acilan C.Evaluation of the molecular mechanisms of a palladium(II) saccharinate complex with terpyridine as an anticancer agent. <i>Anticancer Drugs</i> . 2014 Jan;25(1):17-29

70. Ari F, Aztopal N, Iysel C, Yilmaz VT, Guney E, Ulukaya E . Synthesis, structural characterization and cell death-inducing effect of novel palladium(II) and platinum(II) saccharinate complexes with 2-(hydroxymethyl)pyridine and 2-(2-hydroxyethyl)pyridine on cancer cells <i>in vitro</i> . <i>Bioorg Med Chem</i> . 21(21):6427-34, 2013
71. Ferda Ari,.....xxxx. <i>Parmelia sulcata</i> Taylor and <i>Usnea filipendula</i> Stirt. Induce Apoptosis-Like Cell Death and DNA Damage in Cancer Cells (Accepted by <i>Cell Proliferation</i>).
72. Ari F, Cevatemre B, İkitimur EI, Aztopal N, Yilmaz VT, Ulukaya E. Apoptosis-Inducing Effect of a Palladium (II) Saccharinate Complex of Terpyridine on Human Breast Cancer Cells <i>in vitro</i> and <i>in vivo</i> (Accepted by <i>Bioorg Med Chem</i>)
73. Celikler S, Oran S, Ari F, Ulukaya E , Aztopal N, Sarimahmut M, Ozturk S. Genotoxic, Cytotoxic, and Apoptotic Effects of Crude Extract of <i>Usnea filipendula</i> Stirt. <i>in vitro</i> . (Accepted by <i>Turk J Biology</i>)
74. Adiguzel Z, Baykal AT, Kacar O, Yilmaz VT, Ulukaya E , ACILAN C. The biochemical and proteomic analysis of a potential anticancer agent: Palladium(II) Saccharinate Complex of Terpyridine acting through double strand break formation. (Accepted by <i>Journal of Proteome Research</i>)
75. Inga Marijanovic..... Cytotoxic Activity of Novel Palladium-Based Compounds on Leukemia Cell Lines. (Accepted by <i>Anti-cancer drugs</i>)
76. Azmi Yerlikaya A proteomic analysis of p53-independent induction of apoptosis by bortezomib in 4T1 breast cancer cell line (Accepted by <i>Journal of Proteomics</i>).
77. Karakas D, Cevatemre B, Ulukaya E . Cancer stem cels: Emerging actors in basic and clinical cancer research (Accepted by <i>T J Biol</i>).

ÖDÜLLER

1-“TRAVEL AWARD” ÖDÜLÜ (Boston, USA) Ulukaya E , Stockwin H, Mehmet H and Wood E J. Fenretinide can Induce Cytochrome c Release from Mitochondria into the Cytosol in Squamous Cell Carcinoma Cells. <i>The American Society for Biochemistry and Molecular Biology Meeting. Graduate/Postdoctoral Travel Award Program</i> . 4 June 2000, Boston, USA
2- POSTER ÖDÜLÜ (Selçuk, TÜRKİYE) Ulukaya E , Kurt A, Mehmet H ve Wood EJ. Fenretinide induces apoptosis via cytochrome c release without changing mitochondrial transmembrane potential (Poster dili İngilizce). <i>XVI. Ulusal Biyokimya Kongresi. İkinci Uluslararası Biyobilim Günleri</i> . 23-27 Ekim, 2000, Selçuk, Türkiye
3- Çağdaş Gazeteciler Derneği Bursa Şubesi. 2003 Bilim Ödülü. Bursa, Türkiye
4- “YOUNG INVESTIGATOR AWARD” ÖDÜLÜ (Busan, KORE) Ulukaya E , Colakogullari M, Wood EJ. Interference by anti-cancer chemotherapeutic agents in the MTT □ tumor chemosensitivity assay. The 22 nd World Congress of Pathology and Laboratory Medicine. 30 August-3 September, 2003, Busan, KOREA.
5-“THE MOST PROMISING LABORATORY PHYSICIAN” ÖDÜLÜ ve WASPALM MEDAL (Busan, KORE) Awarded at one of the WasPalm meetings: The 22 nd World Congress of Pathology and Laboratory Medicine. 30 August-3 September, 2003, Busan, KOREA.
6- EWCD SCHOLARSHIP (Istanbul, TURKEY) Awarded at the 4th European Workshop on Cell Death. 11-16 May, 2004. Istanbul, TURKEY.
7- TARK 2008 İKİNCİLİK ÖDÜLÜ S. ULUKAYA, I ALPER, M. KILIÇ, A. YILMAZTEPE, E. ULUKAYA . Karaciğer transplantasyonu sırasında oluşan iskemi-reperfüzyon hasarının gösterilmesinde ümit vaat eden yeni serum biobelirteçleri: M30 antijen ve M65 antijen. TARK 2008, 29 ekim-1 kasım 2008, Antalya.
8- ULUDAĞ ÜNİVERSİTESİ BİLGİLENDİRME VE AR-GE GÜNLERİ Poster 1. ÖDÜLÜ 15-16 Kasım 2011, Bursa
9- ULUDAĞ ÜNİVERSİTESİ YILLIK EN FAZLA YAYIN ÖDÜLÜ, 2012
10- ULUDAĞ ÜNİVERSİTESİ YILLIK EN FAZLA ATIF ÖDÜLÜ, 2012
11. ULUDAĞ ÜNİVERSİTESİ BİLGİLENDİRME VE AR-GE GÜNLERİ, Poster 1. ÖDÜLÜ, 13-15 Kasım 2012, Bursa
12. POSTER İKİNCİLİK ÖDÜLÜ. Kacar O, Adiguzel Z, Yilmaz VT, Cetin Y, Cevatemre B, Arda N, Ulukaya E , Acilan C. Investigation of the molecular mechanisms of a palladium(II) saccarinate complex with terpyridine as an anticancer agent. 1 st International BAU-drug design symposium. 21-23 March 2013, Istanbul, TURKEY.
13. ULUDAĞ ÜNİVERSİTESİ YILLIK EN FAZLA ATIF ÖDÜLÜ, 2013
14. ULUDAĞ ÜNİVERSİTESİ BİLİM ve SANAT ÖDÜLÜ, 2013
15. ULUDAĞ ÜNİVERSİTESİ PATENT ÖDÜLÜ, 2013
16. ULUDAĞ ÜNİVERSİTESİ BİLGİLENDİRME VE AR-GE GÜNLERİ Poster 1. ÖDÜLÜ 12-14 Kasım 2013, Bursa
17. POSTER İKİNCİLİK ÖDÜLÜ Ulukaya E , Sarimahmut M, Karakaş D. BİLİM VE TEKNOLOJİ HAFTASI ETKİNLİKLERİ, 12-14 Mart 2014. Bursa
18. POSTER BİRİNCİLİK ÖDÜLÜ. Omer Kacar, Ibrahim Hatipoglu, Zelal Adiguzel, Veysel T. Yilmaz, Yuksel Cetin, Buse Cevatemre, Nazli Arda, Ahmet T. Baykal, Engin Ulukaya and Ceyda Acilan Ayhan. Evaluation of the Molecular Mechanisms of a Palladium(Ii) Saccharinate Complex with Terpyridine as an Anticancer Agent. 2nd INTERNATIONAL BAU-DRUG DESIGN SYMPOSIUM, 17-19 April 2014, İstanbul
19. POSTER BİRİNCİLİK ÖDÜLÜ. Ferda Ari, Buse Cevatemre, Elif Ilkay Ikitimur, Nazlihan Aztopal, Veysel Turan Yilmaz,

Engin Ulukaya. Initial mechanism insights of potential anti cancer agent, Palladium (II) saccharinate complex of terpyridine. EACR-Sponsored 2nd Anticancer Agents Congress & 5th Multidisciplinary Cancer Research Congress's. 23rd-27th of April 2014, Muğla.

20. POSTER İKİNCİLİK ÖDÜLÜ. Elif Ilkay Ikitimur Armutak, Kivilcim Sonmez, Kadriye Akgun Dar, Gulbin Sennazli, Aysegul Kapucu, Funda Yigit, **Engin Ulukaya.** The Effect Of Apoptosis and Anti-Cancer Activity of a Novel Palladium (II) Complex on EAC in Balb-C Mice. EACR-Sponsored 2nd Anticancer Agents Congress & 5th Multidisciplinary Cancer Research Congress's. 23rd-27th of April 2014, Muğla.

DERGİLERDE YAYIN / DANIŞMA KURULU ÜYELİĞİ

1- Uludağ Üniversitesi Tıp Fakültesi Dergisi

2- Türkiye Klinikleri Tıp Bilimleri Dergisi

3- World Journal of Clinical Oncology

4- Journal of Pediatric Biochemistry

ÜYE OLDUĞU DERNEKLER

a. MOKAD (Moleküler Kanser Araştırma Derneği), **Dernek Başkanı**

b. European Association for Cancer Research (EACR) (**Council Member / Konsey Üyesi**)

c. EORTC (European Organisation for Research and Treatment of Cancer) PathoBiology Group (**Tam Üye**)

d. EORTC (European Organisation for Research and Treatment of Cancer) Pharmacology and Molecular Mechanisms Group (**Tam Üye**)